GENETİK TROMBOFİLİ PANELİ BULGULARININ KLİNİK GÖSTERGELERLE UYUMUNUN RETROSPEKTİF ANALİZİ

Abstract

Amaç: Bu çalışmada, kalıtsal trombofili ilişkili genetik risk faktörleri analiz edilmiş olan hastalarda genotip-fenotip ilişkisinin araştırılması amaçlanmıştır. Gereç ve Yöntemler: Genotip verileri ve tanı anı biyokimya, hemogram ve vitamin düzeylerini kapsayan ayrıntılı fenotip bulgularının tamamı, hasta kayıtlarından retrospektif olarak elde edilmiştir. Araştırılan gen varyantları; Faktör V Leiden (FVL), Faktör II G20210A, MTHFR C677T, MTHFR A1298C, PAI-1 4G/5G, Faktör XIII-V34L olup bunların tanımlanmasında gerçek zamanlı PCR tekniği kullanılmıştır. Bulgular: Çalışmaya dâhil edilen 100 hastadan 49’u serebrovasküler olay (SVO), 36’sı pulmoner emboli (PE), 15’i derin ven trombozu (DVT) tanılıydı ve tanı yaşı ortalamaları 46,81±0,98 (yıl) idi. Tanılarına göre FVL saptanma oranları; PE’de %36,11, DVT’de %33,33 ve SVO’da %16,32 ve F2 G20210A tespit edilme oranları ise; PE’de %8,3, DVT’de %6,66 ve SVO’da %6,12 olarak bulundu. Genotip ile tanı, tanı yaşı, cinsiyet ve tanı anı laboratuvar bulguları arasında anlamlı ilişki bulunamadı. Özgeçmiş hiperlipidemi durumu ile SVO tanısı ve MTHFR bileşik heterozigotluğu arasında anlamlı ilişki vardı (p=0,003; p=0,005, sırasıyla). SVO hastalarının, tanı anı B12 vitamini (VB12) ve D vitamini düzeyleri anlamlı düzeyde düşüktü (p=0,003; p=0,001, sırasıyla). Sonuç: Kalıtsal trombofiliye neden olan genetik mutasyonlar, DVT ve PE’de, SVO’ya göre daha yüksek yaygınlıkta gözlenmiş olsa da, genotip açısından hastalıklar arasında anlamlı bir fark bulunamamıştır. SVO tanılı hastalarda, VB12 ve D vitamini düzeylerinin düşük tespit edilmesi, prospektif ve çok sayıda hasta ile yapılacak çalışmalar açısından yol gösterici olabilir.

Keywords

• Tromboembolizm
• trombofili
• serebrovasküler olay
• faktör V Leiden
• faktör II
• vitamin B12
• vitamin D

Supporting Institution

Yok

Ethical Statement

Çalışma, Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi'nin, Girişimsel Olmayan Klinik Araştırmalar Etik Kurulu tarafından onaylanmıştır (Belge No: 2020-92/03).

Retrospective Analysis of the Concordance of Genetic Thrombophilia Panel Findings with Clinical Indicators

Abstract

Objective: This study aimed to investigate the genotypephenotype relationship in patients with analysed genetic risk factors associated with hereditary thrombophilia. Material and Methods: Genotype data and detailed phenotype findings, including biochemical, haematological and vitamin levels at the time of diagnosis, were obtained retrospectively from patient records. The gene variants investigated were Factor V Leiden (FVL), Factor II G20210A, MTHFR C677T, MTHFR A1298C, PAI-1 4G/5G, and Factor XIII-V34L, and real-time PCR technique was used to identify them. Results: Of the 100 patients included in the study, 49 were diagnosed with cerebrovascular event (CVE), 36 with pulmonary embolism (PE), and 15 with deep vein thrombosis (DVT) and the mean age at diagnosis was 46.81±0.98 (years). According to their diagnoses, FVL detection rates were 36.11% in PE, 33.33% in DVT, and 16.32% in CVE and F2 G20210A detection rates were 8.3% in PE, 6.66% in DVT, and 6.12% in CVE. No significant relationship was found between genotype and diagnosis, age at diagnosis, gender, and laboratory findings at diagnosis. There was a significant relationship between past hyperlipidemia status and CVE diagnosis (p=0.003) and MTHFR compound heterozygosity (p=0.003; p=0.005, respectively). CVE patients also had significantly lower vitamin B12 (VB12) and vitamin D levels at the time of diagnosis (p=0.003; p=0.001, respectively). Conclusion: Although genetic mutations causing hereditary thrombophilia have been observed to be more prevalent in DVT and PE than in CVE, no significant difference in genotype has been found between the diseases. The detection of low levels of VB12 and vitamin D in patients diagnosed with CVE may be indicative for prospective studies involving a large number of patients.

Keywords

• Thromboembolism
• thrombophilia
• cerebrovascular event
• factor V Leiden
• factor II
• vitamin B12
• vitamin D

References

1. Shibeeb S, Al-Rayashi N, Shams N, Hadvan T, Agbani EO, Abdallah AM. Factor V Leiden (R506Q), Prothrombin G20210A, and MTHFR C677T variants and thrombophilia in Qatar Biobank participants: A case control study. Pathophysiology. 2024;31:608-620.
2. Lowe GD. Venous and arterial thrombosis: Epidemiology and risk factors at various ages. Maturitas. 2004;47:259- 263.
3. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095-2128.
4. Lian TY, Lu D, Yan XX, et al. Association between congenital thrombophilia and outcomes in pulmonary embolism patients. Blood Adv. 2020;4:5958-5965.
5. Zhang S, Taylor AK, Huang X, et al. Venous thromboembolism laboratory testing (Factor V Leiden and Factor II c.*97G>A), 2018 update: A technical standard of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018;20:1489-1498.
6. Alnor AB, Gils C, Vinholt PJ. Venous thromboembolism risk in adults with hereditary thrombophilia: A systematic review and meta-analysis. Ann Hematol. 2024;103(10):4285-4294.
7. Altwayan R, Tombuloglu H, Alhamid G, et al. Comprehensive review of thrombophilia: Pathophysiology, prevalence, risk factors, and molecular diagnosis. Transfus Clin Biol. 2025;32(2):228-244.
8. Zöller B, Svensson PJ, Dahlbäck B, Lind-Hallden C, Hallden C, Elf J. Genetic risk factors for venous thromboembolism. Expert Rev Hematol. 2020;13:971- 981.

9. Khan F, Tritschler T, Kahn SR, Rodger MA. Venous thromboembolism. Lancet. 2021;398:64-77.
10. Arshad N, Isaksen T, Hansen JB, Brækkan SK. Time trends in incidence rates of venous thromboembolism in a large cohort recruited from the general population. Eur J Epidemiol. 2017;32:299-305.
11. Cushman M, Tsai AW, White RH, et al. Deep vein thrombosis and pulmonary embolism in two cohorts: The longitudinal investigation of thromboembolism etiology. Am J Med. 2004;117:19-25.
12. Naess IA, Christiansen SC, Romundstad P, Cannegieter SC, Rosendaal FR, Hammerstrøm J.Incidence and mortality of venous thrombosis: A population-based study. J Thromb Haemost. 2007;5:692-699.
13. Arnesen CAL, Veres K, Horváth-Puhó E, Hansen JB, Sørensen HT, Brækkan SK. Estimated lifetime risk of venous thromboembolism in men and women in a Danish nationwide cohort: Impact of competing risk of death. Eur J Epidemiol. 2022;37:195-203.
14. Aldawood, FA. Analysis of thrombophilia test ordering practices at King Fahad Hospital of the University. J. Appl. Hematol. 2023;14(4):295-299.
15. Kujovich JL. Prothrombin thrombophilia. Genereview. Jul 25, 2006. Erişim tarihi 12 Mart 2025. https://www.ncbi.nlm.nih.gov/books/NBK1148/.
16. Varga EA, Kujovich JL. Management of inherited thrombophilia: Guide for genetics professionals. Clin Genet. 2012;81:7-17.
17. Egin ME, Çelik ZB, Kervan Ü, Karahan M, Tatar A. Türkiye'nin Doğu Anadolu Bölgesi'nde venöz tromboembolizm olan hastalarda trombofilik gen mutasyonlarının sıklığının araştırılması. Genel Tıp Derg. 2023;33(3):268-273.
18. Yıldız E, Türkmen FM. Factor V Leiden mutation frequency and geographical distribution in Turkish population. J Transl Int Med. 2020;8(4):268-273.
19. Gurgey A, Haznedaroglu IC, Egesel T, et al. Two common genetic thrombotic risk factors: Factor V Leiden and prothrombin G20210A in adult Turkish patients with thrombosis. Am J Hematol. 2001;67(2):107-111.
20. Satyarthi P, Ray D, Kumar V, et al. Prothrombin G20210A mutation is rare but not absent among North Indian patients with thromboembolic events. Indian J Hematol Blood Transfus. 2024;40(3):522-526.
21. Kupeli E, Verdi H, Simsek A, Atac FB, Eyuboglu FO. Genetic mutations in Turkish population with pulmonary embolism and deep venous thrombosis. Clin Appl Thromb Hemost. 2011;17(6):E87-E94.
22. Chiasakul T, De Jesus E, Tong J, et al. Inherited thrombophilia and the risk of arterial ischemic stroke: A systematic review and meta-analysis. J Am Heart Assoc. 2019;8:e012877.
23. Valeriani E, Pastori D, Astorri G, Porfidia A, Menichelli D, Pignatelli P. Factor V Leiden, prothrombin, MTHFR, and PAI-1 gene polymorphisms in patients with arterial disease: A comprehensive systematic-review and metaanalysis. Thromb Res. 2023;230:74-83.
24. Sarecka-Hujar B, Łoboda D, Paradowska-Nowakowska E, Gołba KS. Coagulation factor XIII Val34Leu polymorphism in the prediction of premature cardiovascular events-the results of two meta-analyses. J Clin Med. 2022;11(12):3454.
25. Kattula S, Bagoly Z, Tóth NK, Muszbek L, Wolberg AS. The factor XIII-A Val34Leu polymorphism decreases whole blood clot mass at high fibrinogen concentrations. J Thromb Haemost. 2020;18(4):885-894.
26. Traub J, Weber MS, Frey A. Differential role of factor XIII in acute myocardial infarction and ischemic stroke. Biomedicines. 2024;12(3):497.
27. Szegedi I, Orbán-Kálmándi R, Nagy A, et al. Decreased clot burden is associated with factor XIII Val34Leu polymorphism and better functional outcomes in acute ischemic stroke patients treated with intravenous thrombolysis. PLoS One. 2021;16(7):e0254253.
28. Majmundar S, Thapa S, Miller ES, et al. Low value of inherited thrombophilia testing among patients with stroke or transient ischemic attack: A three-year retrospective study. J Stroke Cerebrovasc Dis. 2023;32(10):107308.
29. Jasaraj RB, Proskuriakova E, Gaire S, Chaudhary A, Khosla P. Thrombophilia testing in stroke: A case report and review of evidence. Cureus. 2023;15(12):e50348.
30. Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2019;50(12):e344-e418.
31. Cevik B, Yigit S, Karakus N, Aksoy D, Kurt S, Ates O. Association of methylenetetrahydrofolate reductase gene C677T polymorphism with multiple sclerosis in Turkish patients. J Investig Med. 2014;62:980-984.
32. Li WX, Lv WW, Dai SX, Pan ML, Huang JF. Joint associations of folate, homocysteine and MTHFR, MTR and MTRR gene polymorphisms with dyslipidemia in a chinese hypertensive population: A cross-sectional study. Lipids Health Dis. 2015;14:101.
33. Tuz AA, Hoerenbaum N, Ulusoy Ö, et al. Hypercholesterolemia triggers innate immune imbalance and transforms brain infarcts after ischemic stroke. Front Immunol. 2025;15:1502346.
34. Kim E, Yang J, Woo Park K, Cho S. Preventative, but not post-stroke, inhibition of CD36 attenuates brain swelling in hyperlipidemic stroke. J Cereb Blood Flow Metab. 2020;40:885-894.
35. Zhou L, Wang J, Wu H, et al. Serum levels of vitamin B12 combined with folate and plasma total homocysteine predict ischemic stroke disease: A retrospective casecontrol study. Nutr J. 2024;23(1):76.
36. Brøndum-Jacobsen P, Nordestgaard BG, Schnohr P, Benn M. 25-hydroxyvitamin D and symptomatic ischemic stroke: An original study and meta-analysis. Ann Neurol. 2013;73:38-47.
37. Simon J, Sriharsha T, Perumal Kumaresan A, Chand U, Bose S. Impact of vitamin D deficiency on ischemic stroke severity: Insights from a prospective study. Cureus. 2024;16(9):e69376.
38. Kamal K, Tewari J, Bharti V, et al. Serum Vitamin D level as a risk factor and prognostic marker for acute ischemic stroke: A case-control study at a tertiary care centre in Northern India. Cureus. 2023;15(9):e46117.
39. Cui P, Hou H, Song B, Xia Z, Xu Y. Vitamin D and ischemic stroke - association, mechanisms, and therapeutics. Ageing Res Rev. 2024;96:102244.
40. Kim C, Lee SH, Lim JS, et al. Impact of 25- Hydroxyvitamin D on the prognosis of acute ischemic stroke: Machine learning approach. Front Neurol. 2020;11:37.